AAAAAA
Results: 1-25/36
Authors:
Stange, EF
Citation: Ef. Stange, Peptide factors in the intestine and liver, EUR J GASTR, 13(7), 2001, pp. 761-762
Authors:
Fellermann, K
Stange, EF
Citation: K. Fellermann et Ef. Stange, Defensins - innate immunity at the epithelial frontier, EUR J GASTR, 13(7), 2001, pp. 771-776
Authors:
Fellermann, K
Rudolph, B
Witthoft, T
Herrlinger, KR
Tronnier, M
Ludwig, D
Stange, EF
Citation: K. Fellermann et al., Sweet syndrome and erythema nodosum in steroid-refractory ulcerative colitis: Successful treatment with tacrolimus, MED KLIN, 96(2), 2001, pp. 105-108
Authors:
Fuchs, M
Ivandic, B
Muller, O
Schalla, C
Scheibner, J
Bartsch, P
Stange, EF
Citation: M. Fuchs et al., Biliary cholesterol hypersecretion in gallstone-susceptible mice is associated with hepatic up-regulation of the high-density lipoprotein receptor SRBI, HEPATOLOGY, 33(6), 2001, pp. 1451-1459
Authors:
Herrlinger, KR
Noftz, MK
Fellermann, K
Schmidt, K
Steinhoff, J
Stange, EF
Citation: Kr. Herrlinger et al., Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use, ALIM PHARM, 15(3), 2001, pp. 363-369
Authors:
Fuchs, M
Stange, EF
Citation: M. Fuchs et Ef. Stange, Cholesterol and cholestasis: a lesson from the Mdr2 (-/-) mouse, J HEPATOL, 34(2), 2001, pp. 339-341
Authors:
Scheibner, J
Stange, EF
Fuchs, M
Citation: J. Scheibner et al., Indirect evidence that intestinal bile salt absorption in rats and hamsters is under positive feedback control, Z GASTROENT, 39(11), 2001, pp. 929
Authors:
Stange, EF
Riemann, J
von Herbay, A
Lochs, H
Fleig, WE
Scholmerich, J
Kruis, W
Porschen, R
Bruch, HP
Zeitz, M
Schreiber, S
Moser, G
Matthes, H
Selbmann, HK
Goebell, H
Caspary, WF
Citation: Ef. Stange et al., Diagnosis and therapy of ulcerative colitis - results of an evidence-basedConsensus conference of the German Society of Gastroenterology and Metabolic Diseases, Z GASTROENT, 39(1), 2001, pp. 19
Authors:
Fellermann, K
Herrlinger, KR
Witthoeft, T
Homann, N
Ludwig, D
Stange, EF
Citation: K. Fellermann et al., Tacrolimus: A new immunosuppressant for steroid refractory inflammatory bowel disease, TRANSPLAN P, 33(3), 2001, pp. 2247-2248
Authors:
David-Walek, T
Niederstadt, C
Rob, PM
Fricke, L
Latta, K
Steinhoff, J
Stange, EF
Citation: T. David-walek et al., Primary hyperoxaluria type 1 causing end-stage renal disease in a 45-year-old patient, NEPHRON, 87(1), 2001, pp. 80-84
Authors:
Scholmerich, J
Stange, EF
Citation: J. Scholmerich et Ef. Stange, Chronic inflammatory bowel disease - Standards and outlook in pharmacotherapy, INTERNIST, 42(4), 2001, pp. 533
Authors:
Lindemann, G
Grohs, M
Stange, EF
Fellermann, K
Citation: G. Lindemann et al., Limited heat-shock protein 72 induction in Caco-2 cells by L-glutamine, DIGESTION, 64(2), 2001, pp. 81-86
Authors:
Herrlinger, K
Stange, EF
Citation: K. Herrlinger et Ef. Stange, Azathioprine in the treatment of chronic inflammatory bowel diseases, MED KLIN, 95(4), 2000, pp. 201-206
Authors:
Fellermann, K
Steffen, M
Stein, J
Raedler, A
Hamling, J
Ludwig, D
Loeschke, K
Stange, EF
Citation: K. Fellermann et al., Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease, ALIM PHARM, 14(2), 2000, pp. 171-176
Authors:
Fellermann, K
Stange, EF
Citation: K. Fellermann et Ef. Stange, Chronic hepatitis C, common variable immunodeficiency and autoimmune hemolytic anemia. Coincidence by chance or common etiology?, HEP-GASTRO, 47(35), 2000, pp. 1422-1424
Authors:
Ludwig, D
Stange, EF
Citation: D. Ludwig et Ef. Stange, Treatment of ulcerative colitis, HEP-GASTRO, 47(31), 2000, pp. 83-89
Authors:
Herrlinger, KR
Stange, EF
Citation: Kr. Herrlinger et Ef. Stange, The pancreas and inflammatory bowel diseases, INT J PANCR, 27(3), 2000, pp. 171-179
Authors:
Ludwig, D
Schadel, S
Bruning, A
Schiefer, B
Stange, EF
Citation: D. Ludwig et al., 48-Hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension - Double-blind, placebo-controlled study, DIG DIS SCI, 45(5), 2000, pp. 1019-1027
Authors:
Rampton, DS
Neurath, MF
Almer, S
D'Haens, G
Petritsch, W
Stange, EF
Citation: Ds. Rampton et al., Mycophenolate mofetil in Crohn's disease, LANCET, 356(9224), 2000, pp. 163-164
Authors:
Fuchs, M
Reimann, FM
Gaebel, C
Ludwig, D
Stange, EF
Citation: M. Fuchs et al., Treatment of infected pancreatic pseudocysts by endoscopic ultrasonography-guided cystogastrostomy, ENDOSCOPY, 32(8), 2000, pp. 654-657
Authors:
Reimann, FM
Samson, U
Derad, I
Fuchs, M
Schiefer, B
Stange, EF
Citation: Fm. Reimann et al., Synergistic sedation with low-dose midazolam and propofol for colonoscopies, ENDOSCOPY, 32(3), 2000, pp. 239-244
Authors:
Rogler, G
Aschenbrenner, E
Gross, V
Stange, EF
Scholmerich, J
Citation: G. Rogler et al., Intracellular transport of high-density lipoprotein 3 in intestinal epithelial cells (Caco-2) is tubulin associated, DIGESTION, 61(1), 2000, pp. 47-58
Authors:
Heits, F
Stahl, M
Ludwig, D
Stange, EF
Jelkmann, W
Citation: F. Heits et al., Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease, J INTERF CY, 19(7), 1999, pp. 757-760
Authors:
Woywodt, A
Ludwig, D
Neustock, P
Kruse, A
Schwarting, K
Jantschek, G
Kirchner, H
Stange, EF
Citation: A. Woywodt et al., Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease, EUR J GASTR, 11(3), 1999, pp. 267-276
Authors:
Stange, EF
Citation: Ef. Stange, Consequences of results of galenic and clinical studies of budesonide and 5-aminosalicylates in the treatment of Crohn's disease: Conclusion, MED KLIN, 94, 1999, pp. 39-41